Dementia with Lewy bodies is a complex brain disorder that affects thinking, movement, mood, and daily functioning. While there is currently no cure, a combination of medications and therapies can help manage symptoms and improve quality of life for many people living with this condition.

Managing a Complex Brain Condition: What Treatment Can Offer

When someone receives a diagnosis of dementia with Lewy bodies, understanding the available treatment options becomes essential for both the person affected and their loved ones. The main goal of treatment is not to cure the disease, but rather to help control symptoms, slow down its progression where possible, and maintain the best possible quality of life for as long as possible. This approach focuses on addressing the multiple symptoms that can appear—from problems with thinking and memory to difficulties with movement, sleep disturbances, and changes in mood and behavior.^[1]

Treatment planning for dementia with Lewy bodies needs to take into account the stage of the disease and the specific symptoms each person experiences. Not everyone with this condition will have the same combination of symptoms, and the severity can vary greatly from person to person. Some individuals may experience more prominent movement problems similar to Parkinson’s disease, while others may have more issues with thinking abilities and hallucinations. Because of this variability, medical professionals typically recommend a personalized treatment approach that addresses the unique needs of each patient.^[2]

The journey of treating dementia with Lewy bodies involves working closely with healthcare professionals who understand the condition. These may include neurologists, psychiatrists, geriatricians, and other specialists who collaborate to provide comprehensive care. Current medical guidelines support the use of medications originally approved for other conditions, such as Alzheimer’s disease and Parkinson’s disease, which have shown benefits in managing symptoms of dementia with Lewy bodies. At the same time, researchers around the world are actively investigating new therapeutic approaches through clinical trials, offering hope for better treatment options in the future.^[3]

Standard Medications and Therapies Currently Used

The foundation of medical treatment for dementia with Lewy bodies relies on a class of drugs called cholinesterase inhibitors. These medications work by increasing levels of a chemical messenger in the brain called acetylcholine, which helps brain cells communicate with each other more effectively. Three main drugs in this category are used: donepezil (known by the brand name Aricept), rivastigmine (Exelon), and galantamine (Reminyl). Among these, rivastigmine is the only one that has received specific approval from regulatory authorities for treating Parkinson’s disease dementia, which is closely related to dementia with Lewy bodies.^[10]

What makes cholinesterase inhibitors particularly valuable for people with dementia with Lewy bodies is their ability to address multiple symptoms at once. These medications are considered the standard of care for improving thinking abilities, reducing confusion, and helping with fluctuations in alertness. Some research suggests that people with dementia with Lewy bodies may actually respond better to these drugs than those with Alzheimer’s disease. Beyond cognitive benefits, these medications can sometimes help reduce hallucinations and improve psychiatric symptoms, making them a cornerstone of treatment.^[15]

Another medication that doctors may prescribe is memantine (Namenda), which works through a different mechanism than cholinesterase inhibitors. Memantine blocks the effects of a chemical called glutamate when it builds up in excessive amounts in the brain. This drug is typically used for moderate to severe cases of dementia with Lewy bodies, particularly when someone cannot tolerate cholinesterase inhibitors or needs additional symptom control. It may offer benefits in terms of thinking abilities and daily functioning.^[12]

For movement symptoms that resemble Parkinson’s disease—such as stiffness, tremor, slow movement, or shuffling walk—doctors may consider using carbidopa/levodopa, commonly known by the brand name Sinemet. This medication helps the brain produce more dopamine, a chemical messenger involved in controlling movement. However, the decision to use this medication requires careful consideration. If movement symptoms are mild, doctors may recommend not treating them at all to avoid potential side effects. When Sinemet is prescribed, it must be monitored carefully because it can sometimes worsen hallucinations or confusion in some individuals.^[10]

Treating hallucinations in dementia with Lewy bodies presents special challenges. Not all visual hallucinations need to be treated, especially if they are not frightening or disruptive to the person experiencing them. When hallucinations do cause distress or behavioral problems, cholinesterase inhibitors are often tried first. If additional treatment is necessary for safety or quality of life, doctors may cautiously consider newer atypical antipsychotic medications. Among these, quetiapine and clozapine are preferred by most specialists who treat dementia with Lewy bodies. A newer medication called pimavanserin, which was approved specifically for treating psychosis in Parkinson’s disease, represents another option that may be safer for people with Lewy body disorders.^[10]

Sleep problems are extremely common in dementia with Lewy bodies, particularly a condition called REM sleep behavior disorder, where people physically act out their dreams during sleep. This can be dangerous both for the person with the condition and their bed partner. The medication clonazepam is often used to help control these nighttime movements. For people who experience excessive daytime sleepiness or trouble staying awake during the day, doctors may try adjusting other medications first, as some drugs can worsen drowsiness. Establishing good sleep routines and addressing any underlying sleep disorders is also important.^[10]

Problems with mood, particularly depression and anxiety, affect many people with dementia with Lewy bodies. Antidepressant medications may be prescribed to help with these symptoms. Doctors typically choose medications carefully, as some antidepressants can have side effects that might worsen other symptoms of the condition. Non-medication approaches, including counseling and psychological support, also play an important role in managing emotional well-being.^[12]

Common side effects of cholinesterase inhibitors include nausea, vomiting, diarrhea, headaches, tiredness, and muscle cramps. These side effects are usually temporary and may improve as the body adjusts to the medication. Memantine can cause headaches, dizziness, and constipation, though these effects are typically mild. The key to successful medication management is finding the right balance—using the lowest effective dose to achieve symptom control while minimizing unwanted effects.^[12]

Beyond medications, several non-drug therapies contribute significantly to managing dementia with Lewy bodies. Occupational therapy helps identify challenges in daily activities like dressing, eating, or bathing, and provides practical solutions to maintain independence longer. Physical therapy addresses movement problems, helps prevent falls, and maintains mobility and strength. Speech and language therapy can assist with communication difficulties and swallowing problems that may develop as the condition progresses.^[12]

Psychological interventions offer valuable support for both cognitive and emotional symptoms. Cognitive stimulation involves structured activities and exercises designed to keep the mind engaged, potentially slowing cognitive decline and improving quality of life. This might include memory games, problem-solving tasks, or group discussions. Social engagement through activities like memory cafes—informal gatherings where people with memory problems and their caregivers can meet for support—provides both practical help and emotional connection.^[12]

The duration of treatment for dementia with Lewy bodies is typically ongoing, as the condition is progressive and chronic. Medications are usually continued as long as they provide benefit and are well tolerated. Regular follow-up appointments allow healthcare providers to monitor effectiveness, adjust dosages, and modify treatment plans as symptoms change over time. Because dementia with Lewy bodies affects each person differently and progresses at varying rates, treatment needs to be flexible and responsive to changing needs.^[7]

Innovative Approaches Being Tested in Clinical Trials

While current treatments can help manage symptoms, researchers worldwide are working intensively to develop new therapies that might slow down or modify the course of dementia with Lewy bodies. Clinical trials represent the pathway through which promising new treatments are tested for safety and effectiveness before they can become available to everyone. Understanding these research efforts offers hope and may provide opportunities for some people to access cutting-edge treatments.^[13]

Clinical trials typically progress through three main phases. Phase I trials focus primarily on safety, testing a new treatment in a small group of people to understand how the body processes it and what side effects might occur. Phase II trials expand to include more participants and begin evaluating whether the treatment actually works to improve symptoms or slow disease progression. Phase III trials involve large groups of patients and compare the new treatment directly against current standard treatments to determine if it offers meaningful benefits. Only treatments that successfully complete all three phases can be approved for general use.^[13]

One major area of research focuses on understanding the abnormal protein deposits that cause dementia with Lewy bodies. These clumps of a protein called alpha-synuclein build up inside brain cells and damage them. Scientists are investigating therapies that might prevent these proteins from forming clumps, help the body clear them away, or protect brain cells from their harmful effects. Some experimental treatments being studied include antibodies designed to target alpha-synuclein, similar to approaches being developed for other brain diseases.^[13]

Immunotherapy approaches represent an exciting frontier in dementia with Lewy bodies research. These treatments aim to harness the body’s immune system to fight the disease process. Some experimental monoclonal antibodies are being designed to bind to alpha-synuclein proteins and help remove them from the brain. Early-stage clinical trials are testing whether these antibodies can be given safely and whether they reach the brain in sufficient quantities to have an effect. While results are still preliminary, this approach has shown promise in laboratory studies.^[13]

Another avenue of research involves medications that target specific molecular pathways involved in cell damage and death in dementia with Lewy bodies. Scientists are investigating compounds that might protect mitochondria (the power plants of cells), reduce inflammation in the brain, or enhance the brain’s natural cleanup systems for removing damaged proteins. Some of these experimental treatments are still in very early stages of testing, while others are moving into trials with patients.^[17]

Researchers are also exploring whether medications that affect other neurotransmitter systems in the brain might help with specific symptoms of dementia with Lewy bodies. For example, clinical trials are testing new types of drugs for visual hallucinations that work differently from current antipsychotic medications, potentially offering better symptom control with fewer side effects. Experimental treatments for REM sleep behavior disorder are also being investigated, as this symptom can be particularly disruptive and potentially dangerous.^[17]

Clinical trials for dementia with Lewy bodies are being conducted in many countries around the world, including the United States, Europe, and other regions. Each trial has specific criteria for who can participate, typically based on factors such as disease stage, age, other medical conditions, and current medications. Some trials seek people in early stages of the disease, while others may include those with more advanced symptoms. Participating in a clinical trial allows people to access experimental treatments before they become widely available and contributes to advancing scientific knowledge that may help future patients.^[13]

While participating in clinical trials offers potential benefits, it’s important to understand that experimental treatments may not work and could have unknown side effects. Some trials use placebo groups, meaning some participants receive an inactive substance instead of the active treatment being tested, though they are carefully monitored throughout. Before joining any clinical trial, potential participants receive detailed information about the study, including risks and benefits, and must provide informed consent. Healthcare providers can help determine whether a particular trial might be appropriate based on individual circumstances.^[13]

The search for better treatments also includes research into improving diagnosis and monitoring of dementia with Lewy bodies. Scientists are working to identify biomarkers—measurable indicators in blood, spinal fluid, or brain scans—that could help diagnose the condition earlier and more accurately. Earlier diagnosis would allow treatment to begin sooner, potentially preserving more brain function. Some research suggests that certain patterns on specialized brain scans or specific proteins in spinal fluid might help distinguish dementia with Lewy bodies from other types of dementia, though these approaches are still being refined.^[13]

Most common treatment methods

• Cholinesterase inhibitors
  • Donepezil (Aricept), rivastigmine (Exelon), and galantamine (Reminyl) are used to improve cognitive symptoms and reduce confusion
  • These medications increase acetylcholine levels in the brain to help brain cells communicate better
  • May also help control hallucinations and behavioral problems
  • Considered the standard treatment for thinking and memory problems in dementia with Lewy bodies
• Other cognitive medications
  • Memantine (Namenda) works by blocking excessive glutamate effects in the brain
  • Used for moderate to severe dementia or when cholinesterase inhibitors cannot be tolerated
• Movement symptom treatments
  • Carbidopa/levodopa (Sinemet) helps improve Parkinson-like movement problems such as stiffness and tremor
  • Must be used carefully as it can sometimes worsen hallucinations or confusion
  • Not always prescribed if movement symptoms are mild
• Medications for hallucinations and behavior
  • Newer atypical antipsychotic medications like quetiapine or clozapine may be used cautiously when hallucinations are disruptive
  • Pimavanserin is a newer option approved for psychosis in Parkinson’s disease that may be safer for Lewy body disorders
  • Traditional antipsychotic drugs like haloperidol must be avoided due to severe reaction risk
• Sleep disorder treatments
  • Clonazepam helps control REM sleep behavior disorder where people act out dreams
  • Melatonin may be used to improve sleep patterns
• Mood and behavioral support
  • Antidepressant medications for depression and anxiety symptoms
  • Counseling and psychological support
• Non-medication therapies
  • Occupational therapy to help with daily activities and maintain independence
  • Physical therapy for movement problems, fall prevention, and maintaining mobility
  • Speech and language therapy for communication and swallowing difficulties
  • Cognitive stimulation activities to keep the mind engaged
  • Social support through memory cafes and support groups